Article
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
The Lancet. Neurology - 1 Jul 2010
Polman Chris H, Bertolotto Antonio, Deisenhammer Florian, Giovannoni Gavin, Hartung Hans-Peter, Hemmer Bernhard, Killestein Joep, McFarland Henry F, Oger Joel, Pachner Andrew R, Petkau John, Reder Anthony T, Reingold Stephen C, Schellekens Huub, Sørensen Per Soelberg
Abstract excerpt
The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy. In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.